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This review focuses on mechanisms and emerging concepts that drive the science of stroke in a therapeutic
direction. Once considered exclusively a disorder of blood vessels, growing evidence has led to the realiza-
tion that the biological processes underlying stroke are driven by the interaction of neurons, glia, vascular
cells, and matrix components, which actively participate in mechanisms of tissue injury and repair. As new
targets are identified, new opportunities emerge that build on an appreciation of acute cellular events acting
in a broader context of ongoing destructive, protective, and reparative processes. The burden of disease is
great, and itsmagnitudewidens as a role for blood vessels and stroke in vascular and nonvascular dementias
becomes more clearly established. This review then poses a number of fundamental questions, the answers
towhichmay generate new directions for research and possibly new treatments that could reduce the impact
of this enormous economic and societal burden.Introduction
Few neurological conditions are as complex and devastating as
stroke, the second leading cause of death worldwide. Also
called a brain attack, victimsmay suddenly experience paralysis,
impaired speech, or loss of vision due to interruption of blood
flow (ischemia) caused by thrombosis or embolism. Less
frequently (<15%), strokes are caused by hemorrhage or cardiac
arrest. On average, strokes in the USA strike once every 40 s and
cause death every 4 min, with an estimated 41.6% death rate in
2007 (Lloyd-Jones et al., 2009). With an aging population, the
absolute numbers are likely to rise. Among survivors, work
capacity is compromised in 70% of victims, and 30% need
assistance with self-care. Hence, the disease burden is great.
The estimated cost for stroke is 73.7 billion dollars in 2010
(USA) and projected to be 1.52 trillion dollars in 2050 (in 2005
dollars) (Lloyd-Jones et al., 2009). No racial or ethnic groups
are spared, and the problem is global. For example, in the
Russian Federation and China, the estimated death rates per
100,000 population are five to ten times higher than in the USA
(Lloyd-Jones et al., 2009). Hence, stroke is an affliction of
mankind.
For the above considerations and more, there is a compelling
need to accelerate efforts to interrogate the stroke process and
define the links that exist with other conditions such as vascular
and neurodegenerative dementia. It is also crucial to expand the
narrow repertoire of therapeutic opportunities for these devas-
tating conditions. To accomplish this, novel approaches are
required that expand upon our evolving mechanistic under-
standing of the fundamentals of cell survival and death
processes as well as tissue repair. The future depends upon
how successful we are in deciphering these mechanisms and
bringing clarity to the complex interactions between the multi-
plicity of cell and tissue types within brain (Lo et al., 2003). Armed
with this knowledge and its successful therapeutic application,
the field of stroke could be transformed.In this spirit then, this brief review addresses selected issues
fundamental to the science of ischemic stroke and vascular
dementia. It begins with posing questions about stroke risk
factors followed by a discussion of key cell and tissue mecha-
nisms that render brain susceptible as well as tolerant to
ischemic injury, including those promoting tissue protection
and repair. The review ends by highlighting promising treatment
strategies, inspired by these endogenous mechanisms, which
present the opportunity to open new avenues in stroke therapy.
Stroke Risk Factors and Triggers
A stroke risk factor is a characteristic of an individual that
increases the risk for stroke compared to someone without
that characteristic (Hankey, 2006). Some risk factors cannot be
modified, such as a family history of cerebrovascular diseases,
older age, male sex, and Hispanic or Black race (Allen and
Bayraktutan, 2008; Hankey, 2006). Other risk factors are modifi-
able, and their correction reduces the chance of having a stroke
(Table 1). These factors, which often coexist, have been
estimated to account for 60%–80% of stroke risk in the general
population (Allen and Bayraktutan, 2008; Hankey, 2006).
Genome-wide association studies are increasingly being em-
ployed to identify susceptibility genes for stroke (Hegele and
Dichgans, 2010). Although several loci have been identified,
the need for independent replication and the modest effect sizes
have precluded the full assessment of the clinical relevance of
these findings (Hegele and Dichgans, 2010).
How Do Risk Factors Increase the Propensity to Stroke?
Risk factors have profound effects on the structure and function
of blood vessels and on their interface with circulating blood.
Many of the established risk factors alter vascular structure by
promoting atherosclerosis and stiffening of arteries and by
inducing narrowing, thickening, and tortuosity of arterioles and
capillaries (Allen and Bayraktutan, 2008; Iadecola and Davisson,
2008). In brain, these morphological changes are oftenNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 181
Table 1. Major Modifiable Risk Factors for Ischemic Stroke
Classification Risk Factor References
Causala hypertension Lawes et al., 2004a
diabetes Lawes et al., 2004b
hypercholesterolemia Amarenco et al., 2006
cigarette smoking Bonita et al., 1999
atrial fibrillation Hart et al., 1999
valvular heart disease Kizer et al., 2005
ischemic cardiomyopathy Loh et al., 1997
carotid stenosis Rothwell et al., 2003
Probableb hyperhomocysteinemia Wald et al., 2002
increased inflammatory
markers (WBC, CRP,
infection)
Di Napoli et al., 2005
elevated plasma fibrinogen Rothwell et al., 2004
dyslipidemia Holme et al., 2009
patent foramen ovale Nedeltchev et al., 2008
obstructive sleep apnea Culebras, 2009
body mass index Hu et al., 2007
lack of exercise Hu et al., 2005
low fruit and vegetable diet Dauchet et al., 2005
psychosocial stress Simons et al., 1998
a Factors demonstrated in randomized clinical trials to reduce stroke
risk if corrected, or for which a strong, consistent, and independent
association with stroke has been established (Hankey, 2006).
b Factors for which the association with stroke is less firm and/or no
causative role has been established. WBC, white blood cells; CRP,
C-reactive protein.
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andmarked alterations in CBF regulation. Thus, aging, hyperten-
sion, diabetes, and hypercholesterolemia impair vital adaptive
mechanisms that assure that the brain is adequately perfused
(Arrick et al., 2007; Iadecola and Davisson, 2008; Iadecola
et al., 2009; Kitayama et al., 2007). The ability of the endothelium
to regulate microvascular flow is compromised, while the
increase in blood flow evoked by neural activity is suppressed,
resulting in a mismatch between the brain’s energy supply and
demand (Arrick et al., 2007; Iadecola and Davisson, 2008;
Iadecola et al., 2009; Zou et al., 2004a).
Some risk factors, like hypertension and diabetes, impair pro-
tective vascular mechanisms that keep CBF stable during
reductions in blood pressure (cerebrovascular autoregulation),
facilitating the occurrence of ischemia if intravascular pressure
drops (Immink et al., 2004; Kim et al., 2008). These vascular
alterations increase the brain’s vulnerability to ischemia after
arterial occlusion because they compromise the development
of collateral flow arising from adjacent nonischemic vascular
territories, which is vital to the survival of the ischemic perinfarct
zone (see Parenchymal Failure section). In addition to their
vascular effects, some risk factors, like aging and diabetes,
may enhance the intrinsic susceptibility of brain cells to injury,
amplifying the tissue damage produced by ischemia (Biessels
et al., 2002), but the biological bases of this effect are not well
understood. Little is known about the interaction among the182 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.different stroke risk factors and whether their vascular effects
are additive or synergistic. Furthermore, the relative contribution
of parenchymal and vascular factors to stroke risk remains to be
determined.
How Do Risk Factors Alter Cerebral Blood Vessels?
Many cardiovascular risk factors increase production of reactive
oxygen species (ROS) and promote inflammation in systemic
and cerebral blood vessels. The predominant vascular sources
of ROS are the superoxide-producing enzyme NADPH oxidase,
xanthine oxidase, mitochondrial enzymes, and uncoupling of
nitric oxide synthase (NOS), a state in which this enzyme gener-
ates superoxide instead of NO (Faraci, 2006) (Figure 1). Many of
the damaging effects of oxidative stress on blood vessels are
related to the biological inactivation of NO by the free radical
superoxide, which reduces NO bioavailability and prevents its
beneficial effects (Pacher et al., 2007; Schulz et al., 2008).
Thus, loss of the vasoregulatory effects of endothelial NO
leads to vasoconstriction and reduced NO-dependent vascular
responses, with a negative impact on the regulation of microvas-
cular flow (Schulz et al., 2008). Loss of the antiaggregant, anti-
proliferative, and anti-cell adhesion effects of NO promotes
platelet aggregation, leukocyte adhesion to endothelial cells,
and smooth muscle proliferation, key steps in vascular inflam-
mation (Pepine, 2009; Zou et al., 2004b). In addition, ROS can
directly promote inflammation by increasing blood-brain barrier
(BBB) permeability through upregulation of vascular endothelial
growth factor (VEGF) and by inducing the expression of cyto-
kines, matrix remodeling enzymes, including metalloproteases,
and proinflammatory genes through NFkb activation (Marchesi
et al., 2008). One such NFkb-dependent gene product, inducible
nitric oxide synthase, produces large amounts of NO, which alter
vascular structure and function through nitration and nitrosyla-
tion of critical proteins (Gunnett et al., 2005; Guzik et al., 2003;
Lima et al., 2010). Peroxynitrite, a potent nitrating agent
produced by the reaction of NO with superoxide, alters vaso-
motor reactivity by inactivating critical endothelial and smooth
muscle enzymes and by activating the DNA repair enzyme
poly-ADP-ribose polymerase (PARP), which leads to ATP deple-
tion and vascular ion channel dysfunction (Pacher et al., 2007).
Whereas ROS may set the stage for inflammation, vascular
inflammation, in turn, leads to ROSproduction, creating a vicious
circle that enhances vascular damage. Activation of the plasmin-
ogen system by oxidative stress and inflammation promotes
matrix remodeling, smooth muscle cell migration, and intimal
hyperplasia (Nicholl et al., 2006), factors that promote athero-
sclerosis and alterations in vascular structure. Thus, oxidative
stress and vascular inflammation are major pathways through
which risk factors exert their deleterious effects on blood
vessels. However, it remains to be determined how individual
risk factors trigger the activation of one or both of these
processes. This is a critical question for targeting preventive
strategies in patients with specific risk factors.
Why Now? Role of Stroke Triggers
While vascular risk factors increase the likelihood of stroke in
affected individuals, precipitating factors that act as ‘‘stroke
triggers’’ must also be postulated. In some patients, the specific
event responsible for the arterial occlusion can be identified,
e.g., neck trauma leading to dissection and occlusion of the
Figure 1. Major Sources of ROS in Brain and
Blood Vessels
Stroke risk factors and ischemia lead to the
activation of several ROS-generating enzymatic
systems. In ischemia, the increase in cytosolic
Ca2+ activates the superoxide-producing enzyme
NADPH oxidase (NOX), through PKC and NO
derived from neuronal NOS (Brennan et al.,
2009; Girouard et al., 2009). Mitochondria
become depolarized by the Ca2+ overload (Nich-
olls, 2008) and, possibly, by ROS derived from
NADPH located near mitochondria (Girouard
et al., 2009) producing large amounts of super-
oxide. The Ca2+-induced activation of proteases
and/or the pro-oxidant environment convert
xanthine dehydrogenase (XDH) to xanthine
oxidase (XO) (Abramov et al., 2007), a super-
oxide-generating enzyme involved in purine
degradation. Finally, the substrate deprivation
induced by ischemia and the oxidative inactiva-
tion of essential cofactors like tetrahydrobiopterin
(BH4) uncouple L-arginine oxidation from NO
formation by NOS, resulting in superoxide
production (NOS uncoupling) (Fo¨rstermann, 2010). Other potential sources of ROS include enzymes for arachidonic acid or catecholamine metabolism,
but their participation in stroke-induced oxidative stress remains in question (Adibhatla and Hatcher, 2010; Kunz et al., 2007a).
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instances the factors precipitating the ischemic event cannot
be established. Although systemic infections, pregnancy and
puerperium, use of illicit drugs, and mental stress often trigger
a stroke (Elkind, 2007), precisely how these factors exert their
effect remains unclear. Exacerbation of vascular inflammation
and activation of the coagulation cascade are likely to play a
role (Welsh et al., 2009). For example, the added vascular
dysfunction and blood clotting abnormalities, superimposed on
those induced by stroke risk factors, could precipitate vascular
occlusion or hemodynamic insufficiency. This view is supported
by the fact that acute stroke often occurs in the setting of
increased circulating leukocytes and elevated plasma markers
of systemic inflammation and vascular activation, which also
predict a poor outcome (Elkind, 2007; Welsh et al., 2009).
Thus, our understanding of stroke triggers is limited, and mech-
anistic studies addressing these issues would be valuable in the
identification of high-risk cases.
Parenchymal Failure: Why and How Does
the Brain Die during Ischemia?
Because of its high intrinsic metabolic activity and large concen-
trations of the neurotransmitter-excitotoxin glutamate (Choi,
1992), the brain is especially vulnerable to ischemic insult. This
can develop either as a consequence of thrombosis in situ or
following embolic occlusion of a cerebral blood vessel, the latter
usually arising from the heart or atherosclerotic plaques in the
carotid artery and aortic arch. Although neurological dysfunction
occurs within seconds to minutes of vessel occlusion, the evolu-
tion of ischemic injury and cell death continues in stages
for minutes, hours, and even days, depending, in part, upon
the vulnerability of the particular brain region, its cellular constit-
uents, and the extent of residual perfusion.
The responses of blood vessels and their perfusion are
important to the outcome as well. For example, a deficiency of
vasodilating molecules such as endothelial NO enlarges stroke
size (Huang et al., 1996). Early restoration of blood flow by clotlysis and reperfusion decreases ischemic injury, and this may
be achievable by giving recombinant tissue plasminogen
activator (tPA), the only FDA-approved treatment for reestablish-
ing flow and salvaging brain tissue. However, tPA is used in
<10% of patients and even less frequently after 3 hr because
of the risk of hemorrhage into ischemic tissue (NINDS tPA Study
Group, 1995). Moreover, tPA may have other unintended risks
(Kaur et al., 2004), such as injury to the blood-brain barrier by
activating matrix metalloproteinases (Wang et al., 2003) or
excitotoxicity in experimental models (Nicole et al., 2001).
Combination therapies that ameliorate these effects may extend
tPA’s therapeutic window while mitigating the untoward effects
of reperfusion and plasminogen activation (Liu et al., 2004;
Cheng et al., 2006; Murata et al., 2008). Theoretically, that could
prolong tissue viability for hours or even longer, depending upon
the rapid delivery of drug to compromised brain (Ginsberg,
2008).
Whether or not vulnerable brain tissue can be rescued or
protected after a protracted time period in the absence of partial
or complete restoration of blood flow is an unanswered question.
In all likelihood, areas of vulnerable brain do remain viable for
hours after vessel occlusion, at least in some instances. For
example, the hemiparesis that follows middle cerebral artery
occlusion in the baboon was reversible in 73% of animals with
reperfusion at 2–4 hr, compared to 33% and 17% in animals
with reperfusion at 8 and 16–24 hr, respectively (Marcoux
et al., 1982; Crowell et al., 1981; Jones et al., 1981). The chal-
lenge then is to restore adequate blood flow quickly after vessel
occlusion and to protect viable tissue from unleashed mecha-
nisms that lead to cell and tissue demise.
Salvageable versus Nonsalvageable Tissue:
Salvageable Tissue Is the Target for Therapy
Tissue distal to an occluded blood vessel is often heteroge-
neous, meta-stable, and differentially susceptible to ischemic
injury. This meta-stable zone, termed the ischemic penumbra
or perinfarct zone (Astrup et al., 1981), is characterized by signif-
icantly depressed tissue perfusion that is barely sufficient toNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 183
Figure 2. The Ischemic Penumbra
The ischemic penumbra represents compromised but viable brain tissue lying
distal to an occluded blood vessel. The top three MR images in this figure were
taken in the same patient early after occlusion of the middle cerebral artery.
The images are shown in the horizontal plane passing through the lateral
ventricles. ‘‘Stunned but not dead tissue’’ is detected by magnetic resonance
imaging (MRI) techniques that assess (1) the spatial extent of the perfusion or
blood flow deficit that presents as red and yellow areas on perfusion-weighted
imaging (PWI, top middle image) and (2) severely damaged tissue in the
ischemic core that presents as high-intensity areas on diffusion-weighted
imaging (DWI, top left image) (Ebinger et al., 2009). In this patient, the perfusion
deficit is larger than diffusion lesion. The top right image depicts the mismatch
between core areas with a diffusion lesion (dark blue) and the larger areas with
low perfusion (light blue-green). Over hours to days (see text), the core territory
expands due to the complex cascades involving excitotoxicity, oxidative
stress, programmed cell death mechanisms, and inflammation, as the initial
trigger of energy failure ultimately progresses to infarcted tissue. The resulting
infarct is shown in the image at the bottom of the figure and is about the size of
the initial perfusion deficit in this untreated patient. In later stages, some
patients may also partially recover, in part due to endogenous mechanisms
of repair and remodeling (Chopp et al., 2007). MRI scans courtesy of G. Albers,
Stanford.
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normal ionic gradients in the presence of electrical silence and
suppressed protein synthesis. The ischemic penumbra then
denotes an ‘‘at risk’’ region that is functionally impaired but
potentially salvageable. However, unless perfusion is improved
or cells made relatively more resistant to injury, the tissue at
risk dies within a few hours (Lo, 2008a, 2008b). The ischemic
core by contrast refers to the irreversibly damaged tissue distal
to an occluded blood vessel, characterized by <20% of baseline
blood flow levels, depleted ATP stores, and irreversible failure of
energy metabolism (Lo, 2008b). With time, the infarct core
expands into the ischemic penumbra, and therapeutic opportu-
nity is lost. Therefore, detecting a penumbra in patients can help
to identify those who might benefit most from acute treatments
that restore blood flow (thrombolysis or endovascular clot
retrieval) or treatments for the future that render viable brain
more resistant to ischemic injury. For this purpose, magnetic
resonance imaging methods such as perfusion-weighted and
diffusion-weighted imaging are most often used. Perfusion-
weighted imaging measures the spatial extent of blood flow
compromise, whereas diffusion-weighted imaging is thought to
detect the region of attenuated diffusion of water, a putative
surrogate marker for severely damaged brain tissue. The differ-
ence is thought to reflect the ischemic penumbra (Figure 2)
(Ebinger et al., 2009). Although the predictive value of this
method is still debated, perfusion-diffusion mismatch provides
a useful first attempt to define the tissue at risk.
What Are the Prominent Mechanisms Leading
to Cell and Tissue Demise?
Within the ischemic penumbra, multiple mechanisms have been
identified over the past few decades that irreversibly damage
brain tissue (Figure 2). Understanding the contribution of each
informs us about potential therapeutic opportunities and treat-
ment targets. In the area of severely limited blood supply, ATP
utilization continues in the presence of minimal synthesis and
levels drop, leading to acidosis and loss of ionic homeostasis.
As a consequence, cells swell and membranes rupture. How-
ever, ischemic cell death cannot be equated with limited ATP
availability; rather, tissue death develops as a consequence of
numerous ionic, biochemical, and cellular events that impose
overwhelming stresses upon already compromised tissue (see
for review Dirnagl et al., 1999; Lo et al., 2003).
Excitotoxicity
Excitotoxicity and calcium overload are major factors contrib-
uting to the early stages of ischemic cell death. The canonical
pathway asserts that glutamate, the most abundant neurotrans-
mitter, accumulates into the extracellular space as a conse-
quence of energy and ion pump failure, as well as failure of
reuptake mechanisms (Choi and Rothman, 1990). The glutamate
overload leads to prolonged stimulation of AMPA and NMDA
ionotropic receptor subtypes to dramatically enhance the influx
of calcium, sodium, and water into neurons. Massive calcium
influx activates catabolic processes mediated by proteases,
lipases, and nucleases (Ankarcrona et al., 1995). In addition,
activation of nNOS, PLA2, and other Ca2+-dependent enzymes
leads to production of NO, arachidonic acid metabolites, and
superoxide, which act as additional triggers of cell death
(Dirnagl et al., 1999; Lo et al., 2003). For these and other reasons,184 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.
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further ATP depletion, ROS production, and release of stored
Ca2+ from mitochondria, further accelerating a series of cata-
strophic events that lead to acute cell death.
Despite the validation of glutamate toxicity in the laboratory
setting and its enormously positive impact on the quest for
new therapeutics in neuroscience, numerous clinical trials tar-
geting NMDA and AMPA receptors have failed to improve
outcome in stroke patients (Ginsberg, 2009). Although replete
with shortcomings in trial design and implementation, the failure
to translate has reinforced the notion that the glutamate hypoth-
esis may have oversimplified the complexity of the cell death
process and underestimated the diversity of expressing cell
types as well as the heterogeneity of glutamate responses
following receptor overstimulation in stroke. Moreover, it is likely
that NMDA-AMPA pathways comprise only a subset of routines
disrupting ionic imbalance following glutamate receptor activa-
tion. As originally conceived, the NMDA-AMPA model did not
consider the delayed and invariably fatal glutamate-independent
calcium influx following oxygen-glucose deprivation or the failure
of glutamate receptor blockade to halt cell death after very
intense oxygen-glucose deprivation (Aarts et al., 2003). Equally
importantly, it could not account in an obvious way for the death
of nonneuronal cell types such as astrocytes, vascular cells, or
microglia in ischemic tissue. An alternative viewpoint is that the
drugs tested in clinical trials were poorly chosen, because
many of them block all receptor functions (Lipton, 2007a). As
a result, the dosing may have been suboptimal, due to the devel-
opment of untoward side effects that prevented dose escalation
to neuroprotective levels. A more suitable approach would be to
use therapeutic agents that selectively target excessive channel
opening (e.g., uncompetitive inhibitors with a relatively fast off-
rate, such as memantine [Orgogozo et al., 2002; Mo¨bius and
Sto¨ffler, 2002; Lipton, 2006; Kavirajan and Schneider, 2007]),
thereby retaining normal receptor functions (Lipton, 2007a).
To add to the complexity, it is now known that NMDA receptor
location and subunit composition differentially regulate neuronal
survival or death, although the strength of the calcium signal may
specify the fate of neurons best following NMDA overactivation
(Stanika et al., 2009). With notable exceptions, selective
enhancement of synaptic receptors (in which NR2A peptide
subunits predominate over NR2B) promotes neuronal survival,
whereas activating extrasynaptic receptors (in which NR2B
peptide subunits predominate over NR2A) promote cell death
(Chen et al., 2007), in part, by activating death-associated
protein kinase 1 (Tu et al., 2010). Turning CREB-dependent
signaling and BDNF expression up or down is critical for cell
fate determination during NMDA receptor activation. The MAP
kinase family members P38 and ERK1/2 participate, most
likely by phosphorylation-dependent regulation of submem-
brane scaffolding proteins and NR2A and NR2B receptor
subunits (Hardingham et al., 2002). Under ischemic conditions,
the vulnerability to cell death is reduced when postsynaptic
scaffolding proteins are modified, and PSD-95 binding is pre-
vented (Cui et al., 2007). Moreover, successfully targeting the
glutamate receptor complex early on would also diminish the
opening of downstream channels, e.g., transient receptor poten-
tial channels (TRP) and acid-sensing ion channels, as well assuppress the frequency of cortical spreading depolarizations
(see below), ongoing within the ischemic penumbra. Hence,
understanding and leveraging the repertoire of diverse re-
sponses and mediators at the receptor and second messenger
level can only enhance possibilities for successfully targeting
excitotoxicity for the treatment of ischemic injury.
Calcium Dysregulation
It is also known that increased calcium influx from glutamate
receptor overactivation combined with release of Ca2+ from
mitochondria and other stores (e.g., endoplasmic reticulum)
may not fully account for the irreversible buildup of intracellular
Ca2+ after excitotoxic stimulation. Other channels and ion pumps
activated during ischemia in addition to glutamate receptors
have been implicated in the Ca2+ accumulation. These include
the Na+/Ca2+ exchanger (Bano et al., 2007) hemichannels
(Contreras et al., 2004), acid-sensing ion channels (Xiong et al.,
2004), volume-regulated anion channels (Kimelberg et al.,
2006; Simard et al., 2007), and TRP channels (Aarts and Tymian-
ski, 2005). In particular, ASIC1a, activated by ischemia-induced
acidosis, is involved in the Ca2+ influx and its inhibition is neuro-
protective (Simon, 2006). ASICs are stimulated within the pH
range commonly found in ischemic brain tissue, thus explaining
the well-established link between acidosis and worsening of
ischemic outcome in animals and humans. Failure of Ca2+ efflux
mechanisms, especially the Na+/Ca2+ exchanger also contrib-
utes to the Ca2+ accumulation. Prostaglandin E2 EP1 receptors
have a role in the failure of the Na+/Ca2+ exchanger during
ischemia, and their inhibition is markedly neuroprotective (Abe
et al., 2009; Kawano et al., 2006). Therefore, targeting Ca2+
influx-efflux mechanisms may be a valuable approach to coun-
teract Ca2+ dysregulation and associated injury in conjunction
with novel drugs targeting glutamate receptors.
Oxidative and Nitrosative Stress
Oxidative and nitrosative stress are also powerful mediators of
ischemic injury. In one scenario, the redox environment of cells
modulates signal transduction cascades that tip the balance
between prodeath and prosurvival pathways (Crack and Taylor,
2005). In the second scenario, ROS and perhaps reactive
nitrogen species, including peroxynitrite, act directly as execu-
tioners of cell death (Chan, 2001). The brain appears particularly
vulnerable to radical-mediated attack because of its limited
antioxidant defenses (Adibhatla and Hatcher, 2010). Until
recently, it was accepted that during ischemia ROS were gener-
ated principally by mitochondria, a well-known ROS source
during electron transport and oxidative phosphorylation.
However, it was recently shown that NADPH oxidase generates
the majority of superoxide anion produced in vivo and in vitro
during NMDA receptor activation and ischemia (Brennan et al.,
2009; Girouard et al., 2009). Thus, the mitochondrion does not
appear to be the major source of radicals following NMDA
receptor activation. However, the close proximity of NADPH
oxidase to neuronal mitochondria (Girouard et al., 2009) raises
the possibility that this enzyme generates ‘‘kindling’’ ROS that
promote mitochondrial uncoupling, triggering a secondary
ROS surge from mitochondria (Figure 1). These observations
point to NADPH oxidase as a potentially important therapeutic
target in stroke but also highlight the need for a better under-
standing of the interaction among the different ROS sourcesNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 185
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ces. In this regard, a surprising finding has been that activation
of NMDA receptors increases ROS both in neurons and vascular
cells (Girouard et al., 2006), suggesting a role of vascular ROS in
excitotoxic brain damage. Although this observation empha-
sizes the close relationships between vessels and neurons (see
Protecting the Neurovascular Unit), it has not been established
how vascular oxidative stress may contribute to tissue outcome
in excitotoxic brain injury.
NO and related oxidation products are key players in excito-
toxicity. Reactive nitrogen species have important cellular
effects, such as inhibition of key mitochondrial enzymes, facili-
tating mitochondrial transition pore formation, DNA damage,
PARP activation, and activation of Ca2+-permeable TRPM7
channels (Aarts and Tymianski, 2005; Pacher et al., 2007). As a
potential second mechanism, NO modifies protein groups by
covalently attaching to cysteine residues forming S-nitrosothiol
derivatives. This posttranslational modification significantly
impacts cell survival by altering, for example, the function of
critical regulatory proteins such as caspases, metalloproteases
(Gu et al., 2002), and the glycolytic enzyme GAPDH (Nakamura
and Lipton, 2009). As NO has the potential to target a number
of specific cysteine residues to alter protein function, the impact
of S-nitrosylation is (largely) underexplored in the ischemic
process.
Taken together, the experimental evidence implicating oxida-
tive and nitrosative stress in stroke is strong. But the translation
of these fundamental concepts into clinical applications has
proven to be challenging. Most recently, a nitrone-based radical
spin trap failed in the final phase 3 clinical trial for acute ischemic
stroke (Shuaib et al., 2007). And more broadly, the history of
antioxidant therapies in clinical trials for neurodegeneration has
been littered with many disappointments (Kamat et al., 2008).
Overproduction of reactive nitrogen and oxygen species are
surely damaging to brain cells. But at lower, homeostatic levels,
radicals are critical signaling molecules participating in normal
neuronal and vascular function (Faraci, 2006). Finding novel
ways to scavenge or suppress deleterious radicals without
interfering with endogenous signaling will be important to design
effective therapies. As discussed above for excitotoxicity, a
desirable strategy would be to develop drugs that only become
activated by the pathological state intended for inhibition, i.e.,
during oxidative stress (Lipton, 2007b). Another approach would
be to test antioxidant molecules with pleiotropic properties, such
as activated protein-C (APC). APC blocks ROS generation,
suppresses postischemic inflammation, and blocks apoptosis
in neurons and endothelium, thereby providing both paren-
chymal and vascular protection (Yamaji et al., 2005; Cheng
et al., 2006; Liu et al., 2004). APC as well as other pleiotropic
agents with a broad spectrum of activity in experimental stroke
are undergoing clinical trial testing (Ginsberg, 2009).
Cortical Spreading Depolarizations
In addition to excitotoxic events at the molecular and cellular
level, massive release of glutamate and ionic imbalance nega-
tively impact the evolution of ischemic injury at the tissue level.
Cortical spreading depolarization (CSD), a high energy con-
suming phenomenon akin to the cortical spreading depression
of Leao, is triggered by high levels of extracellular glutamate186 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.and K+ and is characterized by slowly propagating massive
depolarization of neurons and astrocytes along with drastic
disruption of ionic gradients (Somjen, 2001). Electrophysiolog-
ical and imaging data convincingly demonstrate CSD in patients
with ischemic stroke (Dohmen et al., 2008). In experimental
animals, a single cortical spreading depolarization expands the
area of severe hypoperfusion by more than 20% (Shin et al.,
2006). In fact, it appears that a greater frequency but more
importantly, duration of DC shifts correspond to accelerated
infarct maturation and core expansion (Mies et al., 1993; Back
et al., 1996). The infarct expansion is probably due to mismatch
between high metabolic demand to support membrane repolar-
ization and marginal tissue perfusion due to constrained penum-
bral blood flow (Back et al., 1996). Hence, suppressing CSDmay
prove worthwhile for reducing infarct maturation. Notably, the
noncompetitive NMDA receptor antagonist ketamine markedly
suppressed CSD frequency in head injury patients (Sakowitz
et al., 2009), but it is unclear whether it improved clinical
outcome. By contrast, irreversible depolarizations resistant to
NMDA receptor antagonists (anoxic depolarization) develop in
the ischemic core territory (Nellga˚rd and Wieloch, 1992) and
are probably terminal events contributing to severe ionic imbal-
ance and tissue failure.
Inflammation
Focal ischemia evokes a robust inflammatory response that
begins within a few hours of onset and typifies the secondary
or delayed response to ischemia. It involves activation of
microglia and astrocytes as well as influx of hematogenous cells
recruited by cytokines, adhesion molecules, and chemokines
across the activated blood vessel wall. Stimulated brain cells
and blood vessels then communicate with one another through
a complex network of paracrine and autocrine signaling. The
highly choreographed response evolves over many days, with
multiple signals and targets triggering expression of novel
proteins and secondary infarct expansion (Kleinig and Vink,
2009). Innate and adaptive immune systems participate as
well. At least early on, inflammation amplifies the ischemic
lesion, but, as discussed later, it may set the stage for tissue
repair in the late postischemic period. A number of therapeutic
trials designed to target the inflammatory response have failed
to show clinical benefit (Sughrue et al., 2004), underscoring the
need to clarify further the complexities of acute and delayed
postischemic inflammatory signaling within brain.
As noted above, cerebral blood vessels are the first to be
exposed to the ischemic insult, and their reaction to injury sets
the stage for the inflammatory response. Early on, production
of cytokines, such as TNFa and IL1b, in vascular cells and
perivascular microglia-macrophages upregulates adhesion
molecule expression (e.g, ICAM-1, P and E-selectin) and, along
with integrins, promote leukocyte rolling and sticking to the
vessel surfaces (Zhang et al., 1998). Neutrophils are the first
blood-borne cells to be recruited into the brain, followed by
monocytes and, starting on days 1–2, lymphocytes. As the
brain’s primary immune cell, activated microglia transform into
macrophages and accumulate at the border zone along with
blood-borne macrophages to clear debris and dead cells and
produce proinflammatory mediators and toxic molecules
(Schilling et al., 2003).
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contribute to the inflammatory response. In particular, products
from cells undergoing oxidative stress and necrosis, for example
lipopeptides, advanced glycation end-products (AGE), modified
lipids, heat shock proteins, hyaluronic acid, and the nuclear
protein HMGB1, lead to activation of the innate immune system
by engaging toll-like receptors (TLRs). TLRs are expressed in
multiple cells and, in conjunction with CD36, receptors for AGE
(RAGE), and other scavenger receptors, may serve to detect
‘‘danger signals’’ triggering NFkb-dependent inflammatory
signaling (Oppenheim and Yang, 2005; Wang et al., 2007).
PARP activity appears to function as an NFkb coactivator (Chiar-
ugi and Moskowitz, 2003), with therapeutic potential for delayed
administration of PARP-1 inhibitors (Kauppinen et al., 2009).
Beside NFkb, other transcriptional activators, including
activator protein-1, STAT-3, interferon regulatory factor 1, and
C/EBP beta, exert a proinflammatory effect (Kapadia et al.,
2006; Iadecola et al., 1999), while PPARgamma acts as a nega-
tive modulator of postischemic inflammation (Kapadia et al.,
2008). In addition to neutrophils and monocytes, T cell subsets
have recently been implicated as modulators of secondary
infarct progression. Treg cells express the antinflammatory
cytokines IL10 and TGFb and normally dampen the immune
response by suppressing T cell effector activity (Liesz et al.,
2009). Secondary infarct progression is impacted by a second
subset of invading T lymphocytes, gamma-delta T cells, a source
of the proinflammatory cytokine IL-17. After deletion of IL-17,
infarct size decreases (Shichita et al., 2009).
These findings support the notion that taming postischemic
inflammation may block secondary events that extend brain
injury. However, as noted below, during the later stages in the
injury process, inflammation promotes critical events necessary
for tissue repair. Therefore, therapeutic interventions targeting
postischemic inflammation should be mindful of temporal
considerations by minimizing the destructive potential of inflam-
mation in the acute phase while enhancing its beneficial contri-
butions to tissue repair in the late stages of cerebral ischemia.
Necrosis, Necroptosis, and Autophagy: The Execution
Necrosis and apoptosis are the principal mechanisms of cell
death after ischemic injury, and the details of both have been
reviewed (Yuan, 2006, 2009). Depending in part upon the magni-
tude, type of stimulus, and cell type, a number of cell death
triggers promote necrosis or apoptosis, although cellular
features of apoptosis and necrosis are sometimes found
together in dying ischemic cells. Probably due to its ATP depen-
dence, apoptotic cell death is prominent after milder injury and is
more delayed (Bonfoco et al., 1995), although severe ischemia is
associated with early-onset caspase cleavage, enzyme activa-
tion, and acute cleavage of substrate proteins (Namura et al.,
1998). Apoptosis and necrosis can be induced by multiple trig-
gers, such as Ca2+ overload or oxidative stress. Mitochondria
play an essential role in both (Schinzel et al., 2005), serving as
a reservoir for proapoptotic and antiapoptotic proteins and cyto-
chrome C. One such protein apoptosis-inducing factor (AIF) is
released from the outer membrane of mitochondria in response
to activation of the nuclear protein PARP and generation of
a PAR polymer, its toxic product (Yu et al., 2006). AIF then trans-
locates to the nucleus to promote a caspase-independent formof cell death, in part by promoting DNA fragmentation and
chromatin condensation. Release of mitochondrial proteins
sets in motion (or suppresses) multiple caspase-dependent
and -independent processes to dismantle critical homeostatic
and repair mechanisms. Despite the expression of executioner
procaspases, activated caspases, and caspase cleavage prod-
ucts, classic apoptotic morphology is rarely found in humans
within adult ischemic brain. However, it does appear more prom-
inently in the ischemic brains of neonates (Ferriero, 2004).
Until now, necrotic cell death was defined as unregulated,
unprogrammed, and lacking cell signaling events. It is the
predominant form of ischemic cell death. It was recently shown
that certain cells, including those within brain, possess a molec-
ular switch that determines whether cells die by necrosis or
apoptosis in a TNF-dependent way (Holler et al., 2000). In this
cell death variation, necrosis is triggered by two kinases, RIP 1
and RIP 3, reciprocally interacting, often in the presence of an
apoptosis inhibitor (Cho et al., 2009). Activated RIP3 is capable
of stimulating enzymes such as the glycogen-degrading enzyme,
glycogenphosphorylase, to steer TNF-inducedapoptosis toward
necrosis, in part through bursting energy metabolism and ROS
generation (Zhang et al., 2009). Nec-1, a small-molecule inhibitor
of RIP-1, decreases ischemic cell injury in models of ischemia-
reperfusion and improves neurological outcome, suggesting
RIP-1 as a potential therapeutic target (Degterev et al., 2005).
Autophagy, an energy-dependent process implicated as a cell
death mechanism, is used by eukaryotes to degrade and recycle
subcellular organelles. Its precise role in the death process is
controversial because autophagic activity may be cytoprotec-
tive, at least in some disease models, e.g., polyglutamine expan-
sions or in aging models (Levine and Kroemer, 2009). In other
disease models, such as in neonatal hypoxia-ischemia, autoph-
agy reportedly promotes cell death (Puyal et al., 2009). Precisely
how this is accomplished remains for further study.
Stroke and Dementia
Themajormechanisms of tissue dysfunction and death reviewed
above develop as a consequence of acute vessel occlusion and
the attendant activation of endogenous mechanisms of cell
injury and tissue demise. More subtle and less well understood
mechanisms are beginning to define a new research frontier
linking cerebrovascular dysfunction and small strokes to the
development of vascular cognitive impairment (VCI) and
Alzheimer’s disease (AD), the most common causes of dementia
(Fotuhi et al., 2009). AD and ‘‘vascular’’ dementia have tradition-
ally been considered distinct entities (Iadecola, 2004). Thus, AD,
the most prevalent of the two, is characterized pathologically by
deposition of the amyloid b peptide (Ab) in the brain parenchyma
(amyloid plaques) and blood vessels (amyloid angiopathy) and
by neurofibrillary tangles (Querfurth and LaFerla, 2010). On the
other hand, cerebrovascular diseases can lead to cognitive
impairment in different ways. For example, a single stroke can
cause dementia by damaging brain regions critical for cognition
(strategic infarct dementia), while multiple strokes can cause
stepwise cognitive deterioration through cumulative brain
damage (multi-infarct dementia) (Leys et al., 2005; Pinkston
et al., 2009). Most often, VCI is due to small white matter lesions
(leukoaraiosis) that are thought to interrupt neural pathwaysNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 187
Neuron
Reviewinvolved in cognition (Pinkston et al., 2009). A recent realization
has been that AD and cerebrovascular diseases coexist in up
to 60% of cases (Leys et al., 2005; Pinkston et al., 2009). Thus,
although cases of ‘‘pure’’ AD and vascular dementia can exist,
in most cases the cognitive decline can be attributed to overlap-
ping cerebrovascular and AD pathologies (Querfurth and La-
Ferla, 2010). The causes of leukoaraiosis and the overlap
between AD and cerebrovascular diseases are discussed in
the next sections.
What Causes the White Matter Damage Underlying VCI?
In the cerebral autosomal-dominant arteriopathywith subcortical
infarctsand leukoencephalopathy (CADASILsyndrome), amono-
genic disease associated with dementia, extensive white matter
damage is caused by notch-3 mutations in vascular smooth
muscle leading to vascular insufficiency (Chabriat et al., 2009).
In common forms of leukoaraiosis, however, the mechanism of
the white matter damage remains unclear, although family
history, hypertension, diabetes, and chronic smoking are well-
established risk factors (Selnes and Vinters, 2006). The white
matter lesions consist of demyelination, axonal loss, enlarged
perivascular spaces, astrogliosis, and microglial activation
(Fernando et al., 2006; Pantoni and Garcia, 1995). The wall of
arterioles is thickened by accumulation of hyalinematerial (lipoia-
linosis) or completely disrupted (fibrinoid necrosis), leading to
microhemorrhages (Fisher, 1968; Pantoni and Garcia, 1995).
Capillary density, resting CBF, and cerebrovascular reactivity
are reduced both in normal and affected white matter (Brown
et al., 2007; Mandell et al., 2008; O’Sullivan et al., 2002).
Disruption of the arteriolar wall by amyloid, as observed in
genetic or sporadic forms of cerebral amyloid angiopathy and
in AD, is also associated with white matter lesions (Weller
et al., 2009). Hypoxia-inducible genes andmarkers of endothelial
activation are upregulated, suggesting hypoxia-ischemia (Fer-
nando et al., 2006). A causative role for hypoxia-ischemia is
also suggested by the fact that the blood supply to the subcor-
tical and basal ganglia white matter is provided by terminal
arterioles located at the watershed between two vascular territo-
ries: perforating arteries from the neocortex and penetrating
branches arising from larger arteries at the base of the brain
(Iadecola et al., 2009). Therefore, these areas may be particularly
susceptible to vascular insufficiency, especially if the structure of
the arterioles and their vasomotor function are altered. On the
other hand, energy and blood flow requirements of white matter
aremuch lower than those of graymatter, rendering the tissue, in
theory, less vulnerable to anoxia-ischemia (Hertz, 2008). There-
fore, alternative mechanisms leading to an increased intrinsic
vulnerability to injury may also play a role. For example, risk
factors for dementia could enhance white matter susceptibility
to anoxia, as aging has been described to do (Baltan et al.,
2008). Disruption of the BBB, an early event in leukoaraiosis,
could lead to injury by producing perivascular edema, microhe-
morrhages, and inflammation, contributing to demyelination
(Farrall and Wardlaw, 2009). Demyelinated axons may be more
susceptible to ischemic injury due to their heightened metabolic
requirements caused by loss of energy-efficient saltatory
conduction and leaky sodium channels (Trapp and Stys, 2009).
Furthermore, dysfunction within the endothelium may compro-
mise the trophic effect that these cells exert on neurons and188 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.glia, contributing to brain dysfunction and damage (see section
on repair mechanisms). Aging, inflammation, hypoxia and,
possibly, other risk factors can also reduce the repair potential
of the damaged white matter by impairing oligodendrocyte
progenitor recruitment and differentiation (Back et al., 2002;
Pang et al., 2010; Sim et al., 2002). Therefore, the mechanisms
underlying leukoaraiosis might be distinct from those of ischemic
cell death and are a fertile ground for new investigations.
Why Does Stroke Increase the Risk of Dementia?
Stroke doubles the risk of developing dementia (Leys et al.,
2005). Although, as discussed above, location, size, and number
of ischemic lesions, as well as leukoaraiosis can account for the
cognitive impairment in some cases, epidemiological and path-
ological evidence indicates that stroke also increases the risk for
AD. Alzheimer pathology can facilitate the development of
dementia in patients with ischemic injury, and, vice versa,
ischemic injury can aggravate the cognitive deficits induced
by AD (Fotuhi et al., 2009). These findings have suggested a
previously unrecognized interaction between amyloid pathology
and ischemic injury. This is not surprising, considering that Ab
has powerful cerebrovascular effects. Ab constricts cerebral
vessels, suppresses vascular reactivity, and impairs autoregula-
tion, leading to vascular insufficiency and increased suscepti-
bility to ischemic injury (Iadecola, 2004; Zhang et al., 1997).
Conversely, ischemia and hypoxia can induce Ab accumulation
by promoting its cleavage from APP (Tesco et al., 2007) and
by downregulating the lipoprotein-related receptor protein-1,
a critical receptor for the vascular clearance of Ab (Bell et al.,
2009; Tesco et al., 2007; Wu et al., 2005). Therefore, in a vicious
cycle, the vascular effects of Ab aggravate ischemia, and, in turn,
brain ischemia enhances Ab accumulation (Iadecola, 2004).
Recent studies have also linked plasma Ab to the white matter
damage underlying leukoaraiosis (Gomis et al., 2009; Gurol
et al., 2006). The significance of this finding and its underlying
mechanisms remain to be defined and placed in context with
other findings showing that Ab could promote axonal injury
directly through its cytotoxic effects (Querfurth and LaFerla,
2010) or indirectly by inducing vasoconstriction and ischemia
(Iadecola, 2004). Therefore, the vascular dysfunction induced
by circulating and parenchymal Ab may act in concert with the
structural and functional vascular changes induced by risk
factors to amplify the vascular insufficiency in small white matter
arterioles leading to white matter injury. However, factors other
than Ab could also contribute to the interplay between AD
pathology and cerebrovascular diseases. For example, cerebral
arterioles of AD patients exhibit a tendency to constrict due to
increased activity of transcription factors (serum response
factor/myocardin) that control the expression of contractile
proteins in smooth muscle cells (Chow et al., 2007). This finding
may play a role in the increased vasoconstrictor tone and
reduced CBF observed in AD (Iadecola, 2004). It remains to be
established whether these changes in gene expression are
related to Ab or to upstream molecular events independent of it.
How Does the Brain Repair Itself after Stroke?
A well-known fact in clinical stroke is that most patients show
some degree of recovery over time. As the brain recovers,
considerable remapping of cortical areas takes place. Functional
Neuron
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dynamic (Dijkhuizen et al., 2003; Chopp et al., 2007). Represen-
tational areas shift as latent networks are unmasked and parallel
circuits are recruited adjacent to damaged regions (Murphy and
Corbett, 2009). More recently, advanced optical imaging
techniques combined with electrophysiology demonstrated
that this remodeling at a circuit level can be correlated with
specific processes of dendritic and synaptic plasticity at a
cellular level (Li and Murphy, 2008). Imaging of mitochondrial
function (Liu andMurphy, 2009) and vascular dynamics (Schaffer
et al., 2006) have provided new insight into how the brain
responds to microvascular perturbations following ischemia.
These powerful tools may eventually allow one to interrogate
mechanisms of stroke recovery at a molecular and cellular level
while testing prorecovery therapies and strategies (Murphy and
Corbett, 2009; Zhang and Chopp, 2009).
Repair and Remodeling Processes after Stroke
Amajor advance within this past decade has been the realization
that adult mammalian brains also exhibit focal areas of ongoing
neurogenesis in the subventricular zone and subgranular zone.
Under normal conditions, these newborn neurons migrate to
olfactory regions and hippocampus. But after cerebral ischemia
or hemorrhage, the birth of new cells seems to increase and
neuroblasts reroute toward damaged brain tissue (Arvidsson
et al., 2002; Parent et al., 2002), perhaps as part of an endoge-
nous attempt by the brain to repair itself. However, whether
these new neurons significantly contribute to functional recovery
remains unclear. Neurogenic responses may persist for surpris-
ingly long periods of time, but themajority of these newborn cells
survive only for a few days (Arvidsson et al., 2002). Whether
these cells develop normally, express neurotransmitters, or
even integrate into existing neural networks remains to be fully
elucidated. Future attempts to promote endogenous neurogen-
esis for therapeutic purposes will have to address ways to
modify parenchymal microenvironments to enhance neuronal
survival and integrate newly born cells into viable circuitry.
In concert with neurogenesis and neural plasticity, the brain
recovering from stroke exhibits complex patterns of vascular
remodeling. Angiogenesis and vasculogenesis in peri-infarct
regions have been detected in rodent models of cerebral
ischemia (Ding et al., 2008) as well as in human stroke (Krupinski
et al., 1996). Indeed, it is now recognized that angiogenic and
neurogenic responses are tightly coregulated after stroke and
brain injury (Arai et al., 2009). This might not be surprising,
because molecular mechanisms of neurogenesis and angiogen-
esis have been evolutionarily conserved so that similar media-
tors and pathways are involved in both phenomena (Carmeliet
and Tessier-Lavigne, 2005). In the normal brain, the neurovascu-
lar niche defines these complex mechanisms of cell-cell sig-
naling between cerebral endothelium and neural precursors in
the subventricular and subgranular zones of ongoing neurogen-
esis. In the context of poststroke recovery, these close relation-
ships between neurogenesis and angiogenesis are maintained.
Neuroblasts migrate along perivascular routes (Thored et al.,
2007). Promotion of neurogenesis enhances vascular regrowth
and, conversely, angiogenic stimulation enhances neurogenesis
(Ohab et al., 2006; Taguchi et al., 2004). Hence, it seems likely
that brain recovery after stroke comprises interdependentneurovascular plasticity and remodeling processes that recruit
multiple common mediators and signals (Snapyan et al., 2009).
The new frontier of neurovascular repair may require a detailed
exploration of how these multicell and multisignal phenomena
are regulated in the context of stroke. Recent experimental
studies have suggested that pharmacologic interventions such
as EPO, statins, activated protein C, and phosphodiesterase
inhibitors may promote functional recovery after cerebral
ischemia (Wang et al., 2004; Zhang et al., 2006; Thiyagarajan
et al., 2008; Chen et al., 2009). Ultimately, therapies that can
augment these endogenous signals and substrates of neurovas-
cular remodeling may have long therapeutic time windows in
stroke (Zhang and Chopp, 2009).
Moving Forward: Charting a Course toward
New Stroke Therapies
Tremendous progress has been made in the understanding of
fundamental mechanisms of neuronal cell death. However, the
translation of these powerful molecular and cellular principles
into clinically effective neuroprotective therapies in stroke has
been challenging. More recently, emerging data from both
experimental and clinical studies now suggest that all cell types
in the brain participate in the complex pathophysiology of brain
injury following stroke. Consequently, therapeutic approaches
should target multiple cell types in an attempt to protect
their structural and functional integrity and their reciprocal
interactions.
Protecting the Neurovascular Unit
The so-called ‘‘neurovascular unit’’ provides a conceptual
framework that integrates responses in all cell types, including
neuronal, glial, and vascular elements (del Zoppo, 2009;
Iadecola, 2004; Zacchigna et al., 2008) (Figure 3). Cell-cell
interactions in the neurovascular unit form the basis for brain
function. Dysfunctional signaling in the neurovascular unit
underlies the basis for disease. Whereas the intricate molecular
pathways of cell death in the neuron have been dissected in
detail, the mechanisms of how the entire neurovascular unit
responds to stroke are not completely understood. As discussed
in the previous sections, cerebral ischemia can rapidly induce
perturbations in cell-cell signaling and function within the neuro-
vascular unit. How each cell type succumbs or adapts to injury is
dependent on responses in other cells. For example, genomic
and proteomic responses in neurons subjected to metabolic
stress have been fairly well described. But how each cell type
might alter its response to vascular risk factors and ischemia in
the context of other elements in the neurovascular unit remains
to be elucidated. As the nexus of cell-cell interactions grows,
a systems biology approach may eventually be required to
rigorously define mechanisms as well as targets for complete
neurovascular protection. The importance of cell-cell signaling
in the neurovascular unit has been underscored by many studies
(Arai and Lo, 2009a, 2009b; Dugas et al., 2008; Eroglu et al.,
2009; Guo et al., 2008). Hence, under normal conditions, trophic
coupling within the neurovascular unit helps maintain homeo-
stasis. In contrast, under diseased conditions, it is likely that
loss of coupling would lead to pathophysiology (Grammas
et al., 1999; Nagai et al., 2007). Loss of trophic coupling is also
likely to play a role in theway vascular risk factors render neuronsNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 189
Figure 3. Remodeling the Neurovascular Unit
This schematic depicts a cerebral blood vessel and surrounding brain parenchyma that comprise the neurovascular unit. The neurovascular unit encompasses
cell-cell and cell-matrix interactions between component vascular, glial, and neuronal cells. Homeostatic signaling in the neurovascular unit sustains normal brain
function. Dysfunctional neurovascular signaling mediates injury after stroke. During the recovery phase after stroke, neurovascular signaling may also be critically
important with repair mechanisms that may involve angiogenesis, vasculogenesis, and endothelial precursor mechanisms. As the blood-brain barrier heals,
inflammation may convert from a deleterious to beneficial role. Reactive glia (astrocytes, microglia, pericytes) may secrete trophic factors. Synaptic and dendritic
plasticity aswell as axonal remyelinationmay provide parenchymal substrates for functional recovery. Emerging data now suggest that these phenomenon do not
occur in isolation. All componentsof theneurovascular unit are likely to remodel coordinately (Arai et al., 2009;Murphy andCorbett, 2009; ZhangandChopp, 2009).
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sis and brain dysfunction underlying cognitive impairment.
Recently, BDNF has been implicated as a candidate factor that
mediates trophic coupling between vascular and neuronal
compartments (Arai and Lo, 2009b; Guo et al., 2008). Insofar
as BDNF polymorphisms have been implicated in modulating
synaptic plasticity (Kleim et al., 2006), these neurovascular
trophic signals may also influence mechanisms of recovery after
stroke.
The concept of the neurovascular unit may provide an
integrated framework for investigating mechanisms and thera-
pies. Salvaging neurons alone may not be sufficient. One has
to protect glial and vascular elements as well. Future investiga-
tions might be better served by pursuing targets that are
expressed on multiple cell types in brain. Furthermore, preven-
tion of cell death alone may also not be sufficient. In order for
therapies to be clinically meaningful, cellular function must be
preserved and/or restored. Neurons that are alive but lack
proper connectivity or do not express the correct array of
transmitter release-reuptake and synaptic activity may not be
functional. Astrocytes that survive but cannot provide hemody-
namic coupling would be unable to link neuronal activation with
the required vascular responses. Oligodendrocytes that are
respiring but metabolically impaired might not provide the
necessary myelination for axonal conduction. Endothelial cells
that survive but do not maintain blood-brain barrier properties
would facilitate damage to adjacent parenchyma. Ultimately,
any stroke therapy must include both prevention of cell death
as well as rescue of integrated neurovascular function.
Ischemic tolerance and postischemic hypothermia are some
of the most potent protective strategies for ischemic brain injury
and represent examples of multimodal therapies targeting the190 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.neurovascular unit as a whole. These are described in the
next sections.
How Does the Brain Protect Itself?
Lessons from Ischemic Tolerance
Some of the very same mechanisms implicated in the tissue-
damaging responses after stroke can also be engaged to protect
the brain after threatened injury and to induce ischemic tolerance
(IT). IT is a concerted organ response to protect itself against
tissue injury and has been widely studied over the past three
decades in an effort to identify endogenous mechanisms of
protection and to exploit them for therapeutic purposes
(Obrenovitch, 2008). In its delayed form, it is induced after
challenge by a subthreshold noxious stimulus, developing within
1–3 days and lasting for several additional days. Experimentally it
can be induced by exposure to preconditioning stimuli such as
neurotoxins (e.g., glutamate), substrate deprivation (e.g.,
ischemia, hypoxia), or inflammation (e.g., cytokines and immune
responses) and engages mechanisms that detect, transduce,
and promote a complex tissue reaction that reflects a funda-
mental genomic reprogramming after threatened injury (Dirnagl
et al., 2009; Gidday, 2006; Stenzel-Poore et al., 2004). In this
altered physiological state, tissue damage is mitigated when
challenged by exposure to a wide range of deleterious stimuli,
even if unrelated to the initial challenge.
It is mediated by highly redundant cellular, molecular, and
physiological mechanisms involving neurons, astrocytes, and
vascular cells (Gidday, 2006). Upstream sensors have been
implicated, including adenosine and its A1 receptor, the NR2A
NMDA receptor subunit, and the transcriptional regulator
hypoxia inducible factor (HIF). HIF is an attractive candidate
because it regulates a constellation of genes, including
those whose protein products facilitate oxygen transport
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transporters), and promote angiogenesis (e.g., VEGF), by way
of example. Unexpectedly, genetic deletion of HIF1a improves
infarct volume after middle cerebral artery occlusion, implicating
as yet unknown pathogenic mechanisms activated by ischemia
(Helton et al., 2005). Erythropoietin, one of the gene products of
HIF1a, promotes PI3 kinase/AKT activity and the expression of
NFkB-dependent protective genes (Digicaylioglu and Lipton,
2001). Erythropoietin also downregulates hypoxia-induced
proapoptotic mechanisms (Noguchi et al., 2007; Prass et al.,
2003; Ruscher et al., 2002), and erythropoietin-based therapies
have been investigated in the clinical arena (Ehrenreich et al.,
2009). Heat shock protein family members are upregulated in
ischemic tolerance and, based on their multiple cytoprotective
actions, may promote survival. Preconditioning stimuli preserve
connexin 43 hemichannels in astrocytes facilitating ATP released
from these cells and increasing the extracellular concentration of
the beneficial nucleoside adenosine (Lin et al., 2008). At the
same time, preconditioning safeguards the function of cerebral
blood vessels from the deleterious effects of cerebral ischemia,
resulting in improved penumbral flow and reduced brain damage
(Kunz et al., 2007b). These astrocytic and vascular changes are
coupled with mechanisms that reduce energy demands, lessen
inflammatory responses and ion channel activity, and decrease
cascades promoting blood clotting and apoptotic cell death
(Dirnagl et al., 2009; Obrenovitch, 2008; Gidday, 2006). Factors
involving mitochondria as well as its uncoupling proteins have
also been suggested and include improved efficiency of ATP
synthesis, preservation of the mitochondrial membrane
potential, and delayed opening of mitochondrial transition pore
formation, as well as opening of mitochondrial ATP-dependent
K+ channels (Dirnagl and Meisel, 2008).
One of the key questions defying explanation at the moment is
how and why diverse preconditioning stimuli targeting single
genes or key steps in seemingly unrelated cascades all impact
infarct injury in genetically engineered and wild-type mice. It
may be telling us that the mechanisms through which the brain
protects itself involve a highly integrated network response
that emphasizes multiple cells within the neurovascular unit. If
true, comparable multicellular approaches are needed that
capitalize on this integrated response in the design of successful
treatments (see next section).
Therapeutic Hypothermia: Engaging Pleiotropic
Mechanisms in Multiple Cell Types
The therapeutic hypothermia field has advanced significantly
during the past decade, inspired by positive outcomes from
clinical trials in cardiac arrest victims (Bernard et al., 2002).
Satisfactory neurological recovery was achieved in about half
of the treated patients when treatment was begun within 2 hr
of cardiac arrest. Promising results were reported in small feasi-
bility studies in neonatal ischemia (Shankaran et al., 2005).
Current efforts are directed toward translating these successes
in cardiac arrest and neonatal ischemia to patients with ischemic
stroke, but there remain unresolved technical issues surrounding
the timing and method for inducing hypothermia, and the delete-
rious effect of rewarming (Wagner and Zuccarello, 2005). It is
now well accepted that hypothermia reduces ischemia in animal
models of stroke, and so far, preclinical results have helpedguide the design of clinical trials in human subjects. Combining
hypothermia with thrombolysis is one example. Experimental
evidence suggests that hypothermia protects the brain
through pleiotropic effects acting on multiple cell types within
the neurovascular unit. Hypothermia reduces brain metabolism,
thereby significantly decreasing oxygen consumption and the
work load of the entire organ (Sakoh and Gjedde, 2003). Hypo-
thermia also reduces glutamate release, ROS production, and
peri-infarct depolarizations. Inflammatory markers decrease,
as well as microglial activation, leucocyte infiltration, MMP
activation, and BBB disruption. In addition, hypothermia sup-
presses apoptotic cell death, decreases mitochondrial release
of cytochrome C and apoptosis inducing factor (see for review
Tang and Yenari, 2010). Cell survival pathways are upregulated
and appear to contribute to the multiplicity of neuroprotective
mechanisms. To what extent each of these promotes tissue
protection or interacts synergistically to enhance tissue survival
is not known and remains for further investigation. Nevertheless,
therapeutic hypothermia does illustrate the potential power of
approaching stroke therapy using combinations of modalities
that engage multiple cell types to enhance protection and
recovery.
Additional Strategies for Repair and Recovery:
Trophic Factors and Cell-Based Therapies
No matter how successful acute neuroprotective strategies
become, many stroke patients may still fall outside of clinical
time windows for effective treatment. Hence, approaches that
promote repair and recovery will be essential for an integrated
stroke armamentarium. Logically, these approaches can be
divided into two categories—pharmacologic or trophic factor
treatments that seek to amplify and augment endogenous
processes of neurovascular plasticity and recovery and cell-
based therapies that seek to replace damaged or lost brain cells.
Many approaches that augment endogenous recovery have
been explored. Growth factors such as NGF, FGF, GDNF, and
BDNF have all met with variable degrees of success in animal
models (Semkova and Krieglstein, 1999). But a limiting factor
in many of these studies is their relatively large molecular weight,
making transport into brain difficult. Some alternatives may yet
exist, such as smaller peptides, transnasal delivery of growth
factors to bypass the blood-brain barrier (Fletcher et al., 2009),
peptidomimetics and compounds that can upregulate endoge-
nous trophic factor production but do not require direct infusion
into brain (Zhang and Chopp, 2009). Additionally, one may also
target inhibitory molecules that accumulate in the area
surrounding the injury and block neuronal repair, such as chon-
droitin sulfate proteoglycans, myelin associated proteins,
NOGO, and semaphorins (Silver and Miller, 2004).
Although stroke-damaged brain usually exhibits varying
degrees of spontaneous recovery, there will always be signifi-
cant areas where endogenous repair is insufficient. In this
regard, cell-based therapies may represent a new frontier. To
date, a variety of cell sources have been tested, including neural
stem cells, bone-marrow-derived mesenchymal cells, as well
endothelial progenitor cells (Koch et al., 2009). Treatments
have typically involved direct transplantations into brain paren-
chyma, catheter infusions into cerebral ventricles, as well as
systemic injections into circulating blood. The latter approachNeuron 67, July 29, 2010 ª2010 Elsevier Inc. 191
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seem to be operational in brain. Infarcted brain tissue upregu-
lates and releases various chemokines, such as SDF-1, to
establish gradients that broadly serve to attract stem and
precursor cell populations (Madri, 2009). Induced pluripotent
stem cells may also provide an alternative cell source to embry-
onic stem cells (Takahashi and Yamanaka, 2006). One advan-
tage is the theoretical possibility that cell repair can be custom
designed to suit specific diseases or individual needs, as
described in a flurry of recent studies showing that neurons
can be successfully derived from pluripotent cells taken from
patients with Huntington’s disease, ALS, and spinal muscular
atrophy (Dimos et al., 2008; Ebert et al., 2009; Park et al.,
2008). Whether similar methods can be applied to stroke victims
remains to be tested.
Overall, cell-based therapies in models of experimental stroke
suggest that delayed repair is a viable treatment approach. But
more work is needed to translate these promising results into
effective stroke therapies. Many questions remain, and the
precise mechanisms of cell-induced repair are still unclear. For
example, do the reported benefits occur because cells are being
explicitly replaced or because transplanted cells serve as
a source of trophic factor production? How well do transplanted
cells survive? Will adjunctive therapies to decrease apoptotic
dropout be necessary? If cells survive, howwell do they integrate
into existing neural or vascular networks? What is the optimum
timing for such therapy? What types of cells should be used?
And finally, what subtypes of stroke patients should be selected
for robust clinical trial results?
As the basic mechanisms of trophic and cell-based repair
continue to be defined, an interesting underlying theme has
emerged that links the survival of newborn or transplanted cells
to the host environment. As discussed in the previous sections,
activated vascular cells and microglia may be detrimental to cell
survival in the early stages of cerebral ischemia, due to produc-
tion of cytokines, ROS, and toxic amount of NO. In the recovery
phase, however, chronically activated microglia may now
secrete beneficial factors such as BDNF and GDNF. Hence, pro-
longed inflammation can serve biphasic roles—dampening
cellular recovery acutely but then enhancing tissue repair later
on. In fact, this principle of biphasic mediators may be broadly
applicable in stroke pathophysiology. There are many examples.
Overactivation of NMDA receptors induces acute excitotoxicity
(Besancon et al., 2008), but without NMDA signaling, chronic
neuronal remodeling cannot take place (Young et al., 1999).
Matrix metalloproteinases degrade and damage neurovascular
substrates in the acute phase (Rosenberg, 2009), but the same
proteases are critically important for neurovascular remodeling
during the recovery phase (Zhao et al., 2006; Lee et al., 2006).
The intracellular mediator HMGB1 promotes necrosis and
expands the core infarct during acute cerebral ischemia (Qiu
et al., 2008), but during the repair phase, HMGB1 release from
reactive astrocytes promotes angiogenesis and synaptic plas-
ticity (Hayakawa et al., 2010a, 2010b) Altogether, the boundaries
between cell death and cell repair may be blurred (Lo, 2008b).
Future studies that dissect these biphasic mechanisms should
prove fruitful if we are to develop clinically meaningful strategies
for both neurovascular protection as well as repair.192 Neuron 67, July 29, 2010 ª2010 Elsevier Inc.ACKNOWLEDGMENTS
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